Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 1.79 MB, PDF document
The objective of this study was to evaluate the diagnostic and prognostic potential of soluble CD163 (sCD163) in patients with pancreatic ductal adenocarcinoma (PDAC). Preoperative serum samples from 255 patients with PDAC were analyzed for sCD163 using a commercially available enzyme-linked immunosorbent assay. The diagnostic value of sCD163 was evaluated using receiver operating characteristic (ROC) curves. The prognostic significance of sCD163 was evaluated by Cox regression analysis and Kaplan–Meier survival curves. sCD163 was significantly increased in patients with PDAC, across all stages, compared to healthy subjects (stage 1: p value = 0.033; stage 2–4: p value ≤ 0.0001). ROC curves showed that sCD163 combined with CA 19-9 had the highest diagnostic potential compared to sCD163 and CA 19-9 alone both in patients with local PDAC and patients with advanced PDAC. Univariate and multivariate analysis showed no association between sCD163 and overall survival. This study found elevated levels of circulating sCD163 in patients with PDAC, regardless of stage, compared to healthy subjects. This suggests that sCD163 may have a clinical value as a novel diagnostic biomarker in PDAC.
| Original language | English |
|---|---|
| Article number | 897 |
| Journal | Cancers |
| Volume | 15 |
| Issue number | 3 |
| Number of pages | 15 |
| ISSN | 2072-6694 |
| DOIs | |
| Publication status | Published - Feb 2023 |
Bibliographical note
Funding Information:
We thank all patients for their participation in the study. We also thank the nurses and doctors for recruiting the patients before treatment. Laboratory technicians Charlotte Falk and Vibeke Hintze Holm, Department of Oncology, Herlev Hospital are thanked for handling the blood samples. Laboratory technicians Marianne Sørensen and Syela Azemovski, Department of Medicine, Herlev Hospital are thanked for the determinations of the plasma concentrations of sCD163. The Department of Oncology, Copenhagen University Hospital-Herlev and Gentofte is thanked for funding the sCD163 ELISA kits.
Publisher Copyright:
© 2023 by the authors.
- biomarker, pancreatic cancer, soluble CD163, tumor-associated macrophages
Research areas
ID: 373513857